


CLAIMS

1. The use of a compound of formula (I) herein:



wherein:

- . **R₁** represents an atom of hydrogen or a linear or branched alkyl (C₁-C₆), alkenyl (C₁-C₆), or alkynyl (C₁-C₆) radical,
- . **X** represents an atom of oxygen, of sulphur or of selenium ;
- . **Y** represents a single bond or a CH₂ group, optionally substituted by one or two lower alkyl groups,
- . **Z** represents an atom of hydrogen or of halogen, or a linear or branched hydroxy or alkoxy group,
- . **A** represents an imidazole, triazole or tetrazole nucleus,
- . **B** represents a group selected from among the groups phenyl, naphthyl, biphenyl or a monocyclic or bicyclic heteroaryl group having 5 to 10 bonds and comprising 1 to 3 heteroatoms, the groups phenyl, naphthyl, biphenyl and heteroaryl being non-substituted or substituted by 1 to 3 groups chosen from among alkyl (C₁-C₆), alkoxy (C₁-C₆), carboxy, formyl, amino, amido, ester, nitro, cyano, trifluoromethyl, or atoms of halogen.

as well as enantiomers and diastereomers of compounds of formula (I),

as well as the salts from the addition to an acid or to a pharmaceutically acceptable base of compounds of the formula (I),

for preparation of a pharmaceutical formulation intended for treatment of cancer or psoriasis.

2. The use according to claim 1, characterized in that, for the compound of formula (I), the group B is selected from among:

- an unsubstituted benzene or benzene substituted in the meta or para position by a group selected from among the groups cyano or nitro, or by an atom of chlorine;
- a pyridine heterocycle.

3. The use according to claims 1 or 2, characterized in that, for the compound of formula (I), R₁ represents an atom of hydrogen or a methyl group.

4. The use according one of the claims 1 to 3, characterized in that, for the compound of formula (I), Z represents an atom of hydrogen or a methoxy group.

5. The use according to one of the claims 1 to 4, characterized in that, for the compound of formula (I), A represents a 1,3-imidazolyl or 1,2,4 triazolyl group.

6. The use according to claim 1, characterized in that the compound of formula (I) is selected from among the following compounds:

- 5-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,3-benzoxazol-2(3*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-3-methyl-1,3-benzothiazol-2(3*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-3-methyl-1,3-benzothiazol-2(3*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-3-ethyl-1,3-benzothiazol-2(3*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,4-benzoxazin-3(4*H*)-one;
- 6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-4-methyl-1,4-benzoxazin-3(4*H*)-one; and
- 7-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-4-methyl-1,4-benzothiazin-3(4*H*)-one;
- 3-Ethyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
- 4-[(2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
- 4-[(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
- 4-[(3-Ethyl-2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl] benzonitrile;
- 3-Methyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzoselenazol-2(3*H*)-one;

- 3-Ethyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzoselenazol-2(3*H*)-one;
- 4-[(3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)(1*H*-1,2,4-triazol-1-yl)methyl] benzonitrile; and
- 4-[(3-Ethyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)(1*H*-1,2,4-triazol-1-yl)methyl] benzonitrile.

7. Aromatase inhibitor compound according to any one of claims 1 to 6 for use as an active ingredient of a medicament.

8. As a novel compound, a compound of formula (I) as defined in any one of claims 1 to 6.